Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
Re: Pfizer lays out ambitious vision for cancer portfolio in bid to reinvigorate its business.
"As of Dec. 31, Pfizer had three oncology blockbusters, including its top-selling breast cancer drug Ibrance, which brought in $4.7 billion in sales last year, and prostate cancer drug Xtandi. Sales of both drugs were down in 2023, and both are expected to lose key patent protections in 2027. "
good timing for a deal if the Zen 3694 combo with Xtandi trial move forward